A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia.

Trial Profile

A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2012

At a glance

  • Drugs Imatinib (Primary)
  • Indications Myelofibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2012 Actual end date (1 Oct 2011) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Planned End Date changed from 1 Mar 2007 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top